IPO - Venetian-1 Acquisition Corp.

Form Type: S-1/A

Filing Date: 2025-06-18

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025055292

Filing Summary: Lomond Therapeutics Holdings, Inc., a biopharmaceutical company focused on developing therapies for hematological malignancies, filed an amendment to its registration statement under the Securities Act of 1933 on June 17, 2025. The registration statement relates to the sale of 32,673,624 shares of common stock, of which 11,402,831 shares were issued in a private placement on November 1, 2024, and additional shares resulting from subsequent closings of that offering. The offering seeks to resell these shares by identified selling stockholders. The company aims to raise funds for the clinical development of its product candidates, primarily lomonitinib, a pan-FLT3/IRAK4 inhibitor, and has plans to advance other licensed products from Eil and Bala Therapeutics. Lomond is classified as a 'smaller reporting company' and an 'emerging growth company', which permits it to adhere to reduced reporting requirements. The company noted risks associated with early-stage development, competition, and the uncertainty of obtaining regulatory approvals for its products. The common stock is not yet traded on any public market but the company has applied for quotation on the OTCQB exchange, intending an offering price of $4.00 per share, leading to an anticipated total offering amount of approximately $130.7 million.